EPNextS Group, a Japanese based leading provider of clinical trial solutions, and Frontage Laboratories, Inc., a US based full-service contract research organization (CRO), have announced a collaboration aimed at addressing the challenges of "Drug Lag" and "Drug Loss" in Japan.

Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir's lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.

Frontage is pleased to announce the appointment of Mr. Henry Gao as President of Asia Pacific. Mr. Gao possesses more than 25 years of experience in leading various functions including finance, audit, investment, project management, compliance and board office. He also has vast experience in leading IPO and M&A projects. From 2018 to 2022 Mr. Gao was a member of the board of directors of Frontage. As the President of Asia Pacific, Mr. Gao will be responsible for oversight of the Group’s operations in the Asia-Pacific region.

Frontage Laboratories has announced an initiative to form Global Drug Discovery Services within the organization. Global Drug Discovery Services will unify all operations in chemistry, biology, ADME/PK and pharmacology at various subsidiaries including Quintara Discovery and ACME Biosciences in the San Francisco Bay Area and BRI in Vancouver, Canada. Through the initiative Frontage can now provide customer-centric, science-driven, end-to-end drug discovery services to its customers around the world.

Frontage Laboratories, Inc., a wholly-owned subsidiary of Frontage Holdings Corporation (HK.1521), is proud to once again be named as a CRO Leadership Awards recipient by the Clinical Leader and Life Science Leader magazine. The publication assesses CROs on 20+ performance metrics in ISR’s annual CRO Quality Benchmarking survey. Frontage received five awards across all categories including Capabilities, Compatibility, Expertise, Quality, and Reliability across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)).

Dr. John Kapeghian, Ph.D., DABT, joins Frontage with over 35 years of experience in global preclinical safety evaluation and development. After working in regulatory and experimental toxicology units at large pharma (Ciba now Novartis) and in contract research (Sierra Biomedical/Charles River), he established his own company, Preclinical Safety Associates, which provides toxicology strategy and regulatory services for over 90 companies worldwide since 2006.

Frontage welcomes James Huang, Ph.D. as Vice President, Corporate Quality Assurance. James is a highly experienced quality and compliance professional with over thirty years of experience. He has a proven track record of success in transforming and modernizing quality operations, ensuring global regulatory compliance, and governance strategies.

Stewart is an accomplished executive, with over twenty years of experience in scientific program management, toxicology and toxicologic pathology, strategic planning, and business development in preclinical contract research. Prior to joining Frontage, Stewart was a site and divisional leader at Inotiv with responsibilities spanning multiple laboratory sites focused on pathology, DMPK (drug metabolism/pharmacokinetics), molecular and cell biology, flow cytometry, and small and large animal vivarium operations.

Frontage Holdings Corporation today announced that Dr. Abdul Mutlib has been promoted to CEO of the company, a role in which he succeeds Frontage’s founder Dr. Song Li, who will remain as Executive Chairman of the Board of Directors. Dr. John Lin has been promoted to President of Frontage Laboratories, Inc., the company’s wholly-owned subsidiary. Dr. Mutlib and Dr. Lin will each assume their new roles effective as of today. As Executive Chairman, Dr. Li will continue to actively participate in the company’s leadership and focus on strategic growth opportunities.